Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis

Table 8

Significance of anti-MX1 autoantibody to predict acute exacerbation in IPF adjusted by parameters at the diagnosis of IPF.

Parameters	Univariate analysis			Adjusted by Cox analysis using parameters selected in Table 5			Adjusted by Cox analysis using GAP stage (I, II, III)
	HR	95% CI	value	HR	95% CI	value	HR	95% CI	value
Anti-MX1 IgG Ab	37.14	0.278–4970	0.148	2.506	0.010–614.2	0.743	1.408	0.005–438.8	0.907
Anti-MX1 IgG Ab >0.237	1.504	0.615–3.679	0.371	0.938	0.366–2.408	0.895	0.790	0.291–2.147	0.664
Anti-MX1 IgA Ab	2.423	0.141–41.59	0.542	236.7	0.602–93185	0.073	25.89	0.040–16680	0.324
Anti-MX1 IgA Ab >0.312	4.432	0.978–20.089	0.054	5.097	1.092–23.791	0.038	4.486	0.993–20.264	0.051
Anti-MX1 IgM Ab	0.659	0.002–280.5	0.893	1.384	0.001–1597	0.928	2.688	0.005–1504	0.759
Anti-MX1 IgM Ab >0.450	NE			NE			NE

MX1, myxovirus resistance protein-1; Ab, autoantibody; IPF, idiopathic pulmonary fibrosis; GAP stage, gender, age, and physiology stage; HR, hazard ratio; CI, confidence interval; Ig, immunoglobulin; Ab, antibody. Significance of each anti-MX1 autoantibodies, definite titer, or positivity more than cutoff values to predict acute exacerbation was evaluated by univariate Cox proportional hazard regression analysis, and HR adjusted by GAP stage was also shown.